Monitor for future data readouts from the ANVS-25002 trial, as enhanced digital biomarker data could strengthen clinical endpoints and support regulatory strategy. No immediate financial impact expected.
Price Chart
Executive Summary
Annovis Bio has partnered with NeuroRPM to integrate an FDA-cleared AI-powered digital biomarker platform into its ongoing open-label Parkinson’s disease trial (ANVS-25002). The technology enables real-time, passive monitoring of core PD symptoms using wearables, complementing biological biomarker data from skin-based alpha-synuclein testing to enhance trial precision and real-world evidence collection.
Key Facts
- Annovis Bio partnered with NeuroRPM to use its FDA-cleared AI platform for real-time monitoring of Parkinson’s symptoms (bradykinesia, tremor, dyskinesia) in the ANVS-25002 open-label study.
- The study is enrolling 500 patients; 90 have been enrolled so far.
- NeuroRPM’s platform uses wearable sensors for passive, continuous data collection in real-world settings.
- Annovis is also using a biomarker test for misfolded phosphorylated alpha-synuclein with >90% sensitivity and specificity.
- Data from both digital and biological biomarkers will be used to assess symptom changes and potential disease modification.
Financial Impact
No financial terms disclosed; likely low-cost operational enhancement
Risk Factors
- Integration challenges with new digital platform may affect data consistency.
- No guarantee that improved monitoring will translate into positive clinical outcomes or regulatory approval.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3258883 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 10, 2026 12w ago | 8-K | $1.86 $1.88 | ▲ +1.08% | ▼ −1.35% | $1.18 (−36.56%) |
May 20, 2026 19w ago | 424B5 | $2.15 $1.73 | ▲ +19.53% | ▲ +19.87% | $1.18 (+45.12%) |
May 19, 2026 19w ago | 424B5 | $2.04 $1.75 | ▲ +14.22% | ▲ +14.96% | $1.18 (+42.16%) |
May 15, 2026 20w ago | 8-K | $2.05 $1.79 | ▼ −12.68% | ▼ −14.26% | $1.18 (−42.44%) |
May 15, 2026 20w ago | Press Release | $2.06 $1.78 | ▲ +13.59% | ▲ +15.71% | $1.18 (+42.72%) |
Apr 10, 2026 25w ago | Press Release | $1.59 $2.26 | ▲ +42.14% | ▲ +33.61% | $1.18 (−25.79%) |
Mar 19, 2026 28w ago | Press Release | $2.67 $1.87 | ▼ −29.96% | ▼ −37.58% | $1.18 (−55.81%) |
Mar 16, 2026 28w ago | Press Release | $2.83 $1.73 | ▼ −38.87% | ▼ −42.65% | $1.18 (−58.30%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access